SG11202012165WA - Formulations/compositions comprising ibrutinib - Google Patents
Formulations/compositions comprising ibrutinibInfo
- Publication number
- SG11202012165WA SG11202012165WA SG11202012165WA SG11202012165WA SG11202012165WA SG 11202012165W A SG11202012165W A SG 11202012165WA SG 11202012165W A SG11202012165W A SG 11202012165WA SG 11202012165W A SG11202012165W A SG 11202012165WA SG 11202012165W A SG11202012165W A SG 11202012165WA
- Authority
- SG
- Singapore
- Prior art keywords
- ibrutinib
- formulations
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18177987 | 2018-06-15 | ||
| PCT/EP2019/065637 WO2019238904A1 (en) | 2018-06-15 | 2019-06-14 | Formulations/compositions comprising ibrutinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202012165WA true SG11202012165WA (en) | 2021-01-28 |
Family
ID=62684687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202012165WA SG11202012165WA (en) | 2018-06-15 | 2019-06-14 | Formulations/compositions comprising ibrutinib |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190381174A1 (en) |
| EP (1) | EP3806824A1 (en) |
| JP (2) | JP2021527097A (en) |
| KR (1) | KR20210021348A (en) |
| CN (1) | CN112292117A (en) |
| AU (1) | AU2019287282A1 (en) |
| BR (1) | BR112020024481A2 (en) |
| CA (1) | CA3100146A1 (en) |
| EA (1) | EA202190045A1 (en) |
| MA (1) | MA52874A (en) |
| MX (1) | MX2020013684A (en) |
| SG (1) | SG11202012165WA (en) |
| WO (1) | WO2019238904A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2755094C1 (en) * | 2020-11-12 | 2021-09-13 | Общество С Ограниченной Ответственностью "Научно-Производственная Компания "Фармасофт" | Dosage form for injection in form of solution and stabilizer for its preparation |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
| ATE404206T1 (en) * | 2004-12-06 | 2008-08-15 | Janssen Pharmaceutica Nv | ORAL SUSPENSION WITH MELOXICAM |
| HUE031334T2 (en) | 2006-09-22 | 2017-07-28 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| MY194911A (en) | 2012-06-04 | 2022-12-22 | Pharmacyclics Llc | Crystalline forms of a bruton's tyrosine kinase inhibitor |
| WO2014004707A1 (en) | 2012-06-29 | 2014-01-03 | Principia Biopharma Inc. | Formulations comprising ibrutinib |
| BR112016009200A8 (en) * | 2013-10-25 | 2020-03-24 | Pharmacyclics Llc | use of a btk inhibitor and a checkpoint immune inhibitor |
| WO2015084892A1 (en) * | 2013-12-02 | 2015-06-11 | Cornell University | Methods for treating b cell proliferative disorders |
| WO2015187848A1 (en) * | 2014-06-04 | 2015-12-10 | Sampath Deepa | Hdac inhibitor and btk inhibitor combinations |
| US20160032404A1 (en) * | 2014-08-01 | 2016-02-04 | Pharmacyclics Llc | Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor |
| JP2017523206A (en) | 2014-08-07 | 2017-08-17 | ファーマサイクリックス エルエルシー | New formulation of breton-type tyrosine kinase inhibitor |
| EP3265084B1 (en) | 2015-03-03 | 2023-11-22 | Pharmacyclics LLC | Pharmaceutical formulations of bruton's tyrosine kinase inhibtor |
| MA41828A (en) | 2015-03-27 | 2018-01-30 | Pharmacyclics Llc | CO-CRYSTALS OF A TYROSINE KINASE INHIBITOR FROM BRUTON |
| WO2016156127A1 (en) | 2015-04-02 | 2016-10-06 | Ratiopharm Gmbh | Co-crystals of ibrutinib with carboxylic acids |
| IL295941A (en) * | 2015-04-06 | 2022-10-01 | Janssen Pharmaceutica Nv | Compositions containing ibrutinib |
| MA43650A (en) | 2016-01-19 | 2018-11-28 | Janssen Pharmaceutica Nv | FORMULATIONS / COMPOSITIONS INCLUDING A BTK INHIBITOR |
| EP3405177A1 (en) | 2016-01-19 | 2018-11-28 | Janssen Pharmaceutica NV | Formulations/compositions comprising a btk inhibitor |
| EA201892284A1 (en) * | 2016-05-27 | 2019-08-30 | Тг Терапьютикс, Инк. | COMBINATION OF ANTIBODY AGAINST CD20, SELECTIVE PI3-KINASE-DELTA INHIBITOR AND BTK INHIBITOR FOR TREATMENT OF B-CELL PROLIFERATIVE DISORDERS |
-
2019
- 2019-06-14 EA EA202190045A patent/EA202190045A1/en unknown
- 2019-06-14 BR BR112020024481-3A patent/BR112020024481A2/en unknown
- 2019-06-14 MA MA052874A patent/MA52874A/en unknown
- 2019-06-14 JP JP2020569159A patent/JP2021527097A/en active Pending
- 2019-06-14 MX MX2020013684A patent/MX2020013684A/en unknown
- 2019-06-14 SG SG11202012165WA patent/SG11202012165WA/en unknown
- 2019-06-14 EP EP19729770.8A patent/EP3806824A1/en active Pending
- 2019-06-14 US US16/441,497 patent/US20190381174A1/en active Pending
- 2019-06-14 KR KR1020217000409A patent/KR20210021348A/en unknown
- 2019-06-14 WO PCT/EP2019/065637 patent/WO2019238904A1/en active Application Filing
- 2019-06-14 CA CA3100146A patent/CA3100146A1/en active Pending
- 2019-06-14 CN CN201980039816.6A patent/CN112292117A/en active Pending
- 2019-06-14 AU AU2019287282A patent/AU2019287282A1/en active Pending
-
2023
- 2023-11-09 JP JP2023191535A patent/JP2024023262A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3100146A1 (en) | 2019-12-19 |
| EA202190045A1 (en) | 2021-03-17 |
| EP3806824A1 (en) | 2021-04-21 |
| AU2019287282A1 (en) | 2020-11-26 |
| WO2019238904A1 (en) | 2019-12-19 |
| JP2021527097A (en) | 2021-10-11 |
| BR112020024481A2 (en) | 2021-03-02 |
| KR20210021348A (en) | 2021-02-25 |
| CN112292117A (en) | 2021-01-29 |
| JP2024023262A (en) | 2024-02-21 |
| MX2020013684A (en) | 2021-03-02 |
| US20190381174A1 (en) | 2019-12-19 |
| MA52874A (en) | 2021-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201811312D0 (en) | Compositions | |
| IL287224A (en) | Novel formulations comprising melflufen | |
| GB201707189D0 (en) | Novel formulations | |
| GB201707188D0 (en) | Novel formulations | |
| GB201809976D0 (en) | Novel formulations | |
| GB201904338D0 (en) | Fluorouracil-containing formulations | |
| PL3563719T3 (en) | Cosmetic compositions | |
| PT4045038T (en) | New formulations | |
| GB201803923D0 (en) | Compositions | |
| SG11202103389WA (en) | Immunogenic compositions | |
| IL290356A (en) | Larazotide formulations | |
| SG11202012165WA (en) | Formulations/compositions comprising ibrutinib | |
| IL284691A (en) | Formulations | |
| GB201707187D0 (en) | Novel formulations | |
| SG11202010097WA (en) | Apixaban formulations | |
| GB201805676D0 (en) | Compositions | |
| GB201801425D0 (en) | Compositions | |
| GB201911063D0 (en) | Formulations | |
| GB201905105D0 (en) | Formulations | |
| GB201910092D0 (en) | New formulations | |
| GB201910093D0 (en) | New formulations | |
| SG11202011823SA (en) | Activator-nucleator formulations | |
| GB202117828D0 (en) | New formulations | |
| GB201819028D0 (en) | Butanol-based formulations | |
| GB201910450D0 (en) | Cosmetic compositions |